Imaging Diagnostic Systems Ships Second CT Laser Mammography System To Czech Republic

FORT LAUDERDALE, Fla., Aug. 1 /PRNewswire-FirstCall/ -- Imaging Diagnostic Systems, Inc., announced that a second CT Laser Mammography (CTLM(R)) system has been shipped to the Czech Republic. The CTLM system will be placed at the 3rd Faculty Hospital in Prague.

(Logo: http://www.newscom.com/cgi-bin/prnh/20040412/IMDSLOGO )

"Following the clinical protocols at the Polak Family Breast Diagnostic Center in Prague, we are pleased to announce the placement of another system in the Czech Republic," stated Michal Srb, President of EDOMED A.S. "The 3rd Faculty Hospital features a large oncology ward, which will use the CTLM system in breast examinations. We expect a high volume of studies, which will complement the work done at the Polak Center with CTLM as a screening adjunct."

CTLM exams will be conducted under the direction of Dr. Bohuslav Svoboda, CSc, Dean of 3rd Faculty Hospital.

"We look forward to having Dr. Svoboda and the 3rd Faculty Hospital as part of our growing community of CTLM users," stated Deborah O'Brien, IDSI Senior Vice President. "We are pleased to have a CTLM system placed at such a well-regarded institution and will be anticipating the clinical results."

Imaging Diagnostic Systems is seeking FDA Premarket Approval (PMA) for its Computed Tomography Laser Mammography (CTLM(R)) system to be used as an adjunct to mammography. The FDA has determined that the Company's clinical investigation is a non-significant risk (NSR) investigational device study because it does not meet the definition of a significant risk (SR) device under 812.3(m) of the investigational device exemptions (IDE) regulation (21 CFR 812). The CTLM(R) system is the first patented breast imaging system that utilizes state-of-the-art laser technology and patented algorithms to create 3-D images of the breast. It is a non-invasive, painless examination that does not expose the patient to radiation or require breast compression. The CTLM system is limited by United States Federal Law to investigational use only in the United States. Imaging Diagnostic Systems has received CE Marking, CMDCAS (Canada), Canadian License, China SFDA approval, UL listing, ISO 9001:2000, ISO 13485:2003 certification and FDA export certification for its CT Laser Mammography system.

Please visit Imaging Diagnostic Systems' website at: http://www.imds.com for additional information.

As contemplated by the provisions of the Safe Harbor section of the Private Securities Litigation Reform Act of 1995, this news release may contain forward-looking statements pertaining to future, anticipated, or projected plans, performances and developments, as well as other statements relating to future operations. All such forward-looking statements are necessarily only estimates or predictions of future results or events and there can be no assurance that actual results or events will not materially differ from expectations. Further information on potential factors that could affect Imaging Diagnostic Systems, Inc., is included in the Company's filings with the Securities and Exchange Commission. We expressly disclaim any intent or obligation to update any forward-looking statements.

Investor Relations: Rick Lutz 404-261-1196 lcgroup@mindspring.com

Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/20040412/IMDSLOGOAP Archive: http://photoarchive.ap.orgPRN Photo Desk, photodesk@prnewswire.comImaging Diagnostic Systems, Inc.

CONTACT: Rick Lutz, +1-404-261-1196, or lcgroup@mindspring.com, forImaging Diagnostic Systems

Web site: http://www.imds.com/